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Summary Loss of the RB1 gene is an important event in the initiation and progression of many tumours.
Prostate tissue from 43 patients with prostate cancers and ten with benign prostatic hypertrophy (BPH) were
studied for loss of heterozygosity of the RBI gene. Four intragenic polymorphic loci were studied with two
techniques. These were restriction fragment length polymorphism (RFLP), Southern blotting and hybridisation
with the pl23ml.8 and p68RS2.0 probes (to introns 1 and 17 respectively) and also the polymerase chain
reaction (PCR) to amplify loci within introns 17 and 20. Protein product (pRB) expression was determined by
immunohistochemistry using the NCL-RB antibody in nine patients with cancer and four patients with BPH.
Loss of heterozygosity was found in 24 out of 40 (60%) informative patients with cancer. Loss of RB1
occurred with a similar frequency in early-stage and low-grade cancers as in more advanced cancers. Loss of
RBI was also found in one patient with BPH. Expression of pRB was completely absent from seven cancers
and markedly reduced in the other two, while nuclear pRB staining was always present in areas of BPH,
whether alongside cancer-containing tissue or with BPH alone. We conclude that loss of RB1 is an early event
in prostatic tumorigenesis.
Carcinoma of the prostate is one of the commonest tumours
in men (Hutchinson, 1981). Latent prostate cancer occurs in
5% of men aged 40-49 years, rising to 40% or more of men
aged over 80 years (Wynder et al., 1971; Holund, 1980).
Despite a similar incidence oflatent disease in different coun-
tries, clinically apparent disease is variable. The highest
incidence is seen in US blacks (95.7 cases per 105 males per
annum) and the lowest in the Far East (Zaridze & Boyle,
1987). Mortality varies from 24 deaths per 105 males per year
in US blacks to 12 deaths per 105 males per year in England
and Wales (Zaridze & Boyle, 1987). Death from localised
prostate cancer is uncommon partly because it tends to affect
elderly men and partly because of its slow growth (Blute et
al., 1986; George, 1988). There is a need to identify those
tumours that are likely to progress sufficiently to become
symptomatic.
The retinoblastoma susceptibility gene (RB1) was first
localised to chromosome 13ql4.1 by cytogenetic studies
(Yunis & Ramsay, 1978). The gene was cloned by Friend et
al. (1986) and was the first tumour-suppressor gene to be
identified (Benedict et al., 1990). Osteosarcomas occur with
an increased incidence in surviving adults with hereditary
retinoblastoma and show the same mechanism of RB1 loss as
in retinoblastoma (Friend et al., 1986). Loss of heterozy-
gosity (LOH) per se does not indicate that inactivation of a
gene at that locus is important in the malignant process: a
'background' LOH rate of up to 15% was noted in nearly
two-thirds of polymorphic markers studied in colorectal
cancer (Vogelstein et al., 1989). Higher rates of allelic loss are
more suggestive of a causal role, especially when inactivating
mutations of the gene are also found. Both allele loss and
RB1 mutations have been documented in a substantial pro-
portion of small-cell lung cancers (Harbour et al., 1988),
sarcomas (Wunder et al., 1991), breast cancers (Lee et al.,
1988; T'Ang et al., 1988; Varley et al., 1989) and bladder
cancer (Yandell et al., 1989; Cairns et al., 1991) and in other
various tumours. The protein product of the RB1 gene (pRB)
has a pivotal role in the control of the cell cycle, blocking
entry into the S-phase when dephosphorylated (Hinds el al.,
1992).
Bookstein et al. (1990a) reported that one of seven prostate
cancers had complete loss of pRB expression as determined
by immunoblot analysis and immunostaining of pathology
sections. Both RB1 alleles were inactivated: one by a deletion
within the promoter region, the other by allelic loss. Trans-
fection of the wild-type RB1 gene into the prostate cancer
cell line DU145 (which otherwise expresses an abnormally
truncated pRB) resulted in suppression of the malignant
phenotype (Bookstein et al., 1990b). A preliminary study
within our unit, based on small numbers, showed LOH of
the RB1 locus in six out of nine informative prostate cancer
cases (Phillips et al., 1994). In the present study of43 cancers
we found LOH of the RBl locus in 24 out of 40 (60%)
informative cases. Allelic loss was found to be as frequent in
the early as in the late stages of cancer progression. Absent




Seventy prostate tumours and ten benign hyperplasia (BPH)
specimens were obtained from men undergoing transurethral
resection of the prostate for obstructive symptoms. Venous
blood was take as a source of normal genomic DNA.
Tumours were staged according to the TNM system (UICC,
1978) by digital rectal examination and bone scans. Nodal
status was unknown.
Microdissection of selected tissue was undertaken on
frozen sections (Vogelstein et al., 1988). The diffuse nature of
tumour infiltration in 27 cases meant that it was not possible
to microdissect out small tumour foci in these samples, which
were not used for further study. This left 43 tumours
(numbered 1-43) and ten BPH (labelled A-J) controls for
evaluation. Paired prostate and leucocyte samples were
digested with proteinase K, then extracted with phenol,
phenol/chloroform, chloroform and the DNA ethanol precip-
itated at -20°C (Sambrook et al., 1989). Paired tumour/
normal DNA samples were examined for loss of heterozygo-
sity (LOH) at four loci within three introns (introns 1, 17 and
20) using two methods.
Correspondence: S.M.A. Phillips.
Received 5 January 1994; accepted in revised form 27 June 1994.
Br. J. Cancer (1994), 70, 1252-1257 (D Macmillan Press Ltd., 1994LOSS OF RBI GENE IN PROSTATE CANCER 1253
LOH by restrictionfragment length polymorphism (RFLP)
analysis
Restriction enzyme digest (RsaI and BamHI, Boehringer
Mannheim) of 10yg samples of DNA was followed by
Southern blotting and hybridisation of the resulting filters
(Hybond N, Amersham UK) with radiolabelled probes.
Twenty-five ng of probe was labelled with [x-32P]dCTP by the
random primer techique (Feinberg & Vogelstein, 1984).
Filters were hybridised overnight at 65°C in 0.23 M disodium
hydrogen phosphate in 7% SDS. Sonicated human placental
DNA was added as a blocking agent. They were then washed
with solutions of increasing stringency and exposed to auto-
radiographic film. Two intragenic probes were used. Probe
p68RS2.0 reveals a RsaI polymorphism (eight alleles between
1.5 and 2.0 kb long) within a variable number tandem repeat
(VNTR) sequence in intron 17 of the RB1 gene (Wiggs et al.,
1988). Probe pl23ml.8 reveals a BamHI polymorphism (two
alleles, 4.5 and 2.2/2.3 kb long) to the 5' end of the RB1 gene
within intron 1 (Greger et al., 1989).
LOH usingpolymerase chain reaction (PCR)
Primers to RB1 introns 17 (Greenwald et al., 1992) and 20
(Onadim et al., 1992) were used in PCR reactions to amplify
across polymorphic regions. PCR to intron 17 reveals a XbaI
polymorphism (two alleles, 190 and 123/55/12 bp long). PCR
to intron 20 reveals a VNTR (26 alleles, from 300 to 350 bp
long). Conditions were optimised for each set ofprimers used
(Table I). By mixing DNA from homozygotes in different
proportions, loss of heterozygosity with varying degrees of
'contamination' could be simulated, as described by McDaniel
et al. (1991). Using this model we were able to check in
preliminary studies that the PCR conditions used could
detect LOH, even with significant benign tissue contamina-
tion.
A 100 ng sample of DNA was amplified, typical conditions
being: reaction volume, 25 "l; Taq polymerase, 2 units (HT
Technologies); primers, 60 ng each; and total NTPs, 0.4 mM.
For intron 17, 23 cycles of amplification were used; for
intron 20, 35 cycles. All PCR reactions were carried out in
the presence of [x-32P]dCTP, which was incorporated into the
PCR products as described by Onadim et al. (1992). This
technique allowed greater incorporation of radioactivity into
the PCR products, enabling quicker visualisation of results.
This method of labelling was also preferable to primer end
labelling, as PCR followed by restriction enzyme digest
would have given labelled restriction enzyme fragments of
such disparate size that visual and densitometric analysis of
results would have been difficult.
For intron 20, the PCR products were loaded directly into
the wells. For intron 1 a 5 jl aliquot was digested overnight
at 37°C with 20 units of XbaI and the resulting digest
Table I Details of polymerase chain reaction











Two alleles, 190 and 123 +55+ 12 base pairs
'Hot start', reaction heated to 95°C for 10 min
before DNA added. Then:
1 x 95°C for 10 min, 62°C for 1 min, 72°C for
1 min






26 alleles, 300-350 base pairs long.
1 x 95'C for 15 min, 30 x 95°C for 20 s, 59°C for
20 s, 72°C for 60 s
3'
fragments loaded. Fragments were separated by electropho-
resis in 6% non-denaturing polyacrylamide gels incorpor-
ating 10% glycerol (similar to those used for single-strand
conformation polymorphism analysis). Gels were run at low
power so that no heating occurred and the DNA strands did
































































loss of heterozygosity for each locus
examined
Locus
Intron I Intron 17 Intron 17 Intron 20




































































































































DEL, deletion; inf, informative, no LOH; -, non-informative; np,
PCR amplification to RB intron 17 was not performed; ns, PCR
reaction was not successful in amplifying both tumour and normal pair
for RB intron 20; REAR, rearrangement with novel allele.1254 S.M.A. PHILLIPS et al.
not separate. After electrophoresis the gels were dried and
applied to autoradiographic film. Results were assessed
visually and then checked using densitometry.
All tumour and BPH samples were hybridised with probes
p123ml.8 and p68RS2.0 and amplified using PCR to intron
20. Patients who were non-informative to all of these three
loci, were informative but showed no loss of heterozygosity,
or were cases of special interest were additionally examined
using PCR to intron 17. Cases showing deletions had the
RFLP and/or PCR reactions repeated to confirm the result.
Particular care was taken to confirm results in those patients
in whom just one locus showed a deletion. All cases of LOH
were confirmed using densitometry.
Immunohistochemistry
Nine patients with cancer and four with BPH were selected
at random, and paraffin sections cut at 3 lsm from their
original histology blocks. The streptavidin-biotin complex
method was used to demonstrate Rb protein. Sections were
mounted on Vectabond (Vector laboratories) treated glass
slides, dewaxed in xylene, then rehydrated through graded
alcohols to water. The sections were then placed in a citrate
buffer bath (pH 6) and microwaved (750 W) for 30 min (Nor-
ton, 1993). They were then rinsed with water, bathed in 1%
hydrogen peroxide in methanol, rinsed in water and
incubated with the mouse monoclonal antibody NCL-RB
(NovoCastra Laboratories), diluted to optimum with 0.01 M
PBS. After 1 h the sections were washed in 0.01 M PBS and
the primary antiserum labelled with streptavidin-biotin com-
plex-horseradish peroxidase (Duet Kit; K492, Dako). The
horseradish peroxidase was visualised with 3,3'-diamino-
benzidine tetrahydrochloride as a substrate and the nuclei
counterstained for interpretation (Cattoretti et al., 1992).
Immunohistochemical staining showed pRB to be within the
cell nucleus. In common with another immunohistochemical
study of pRB using a different antibody (RBl-Ab20; Varley
et al., 1989), epithelial cells (tumour and benign), monocytes
and endothelial cells may stain positively, but stromal cells
N T a
do not. In those cells showing loss of nuclear pRB, some
cytoplasmic staining was apparent. Benign epithelial cells
staining positively within the nucleus sometimes also showed
punctate staining within the cytoplasm. The sections stained
for pRB by immunohistochemistry were assessed by the
intensity of cell nuclear and cytoplasmic pRB staining and
the percentage of cells showing loss of staining in these
compartments for tumour, BPH, stroma and other benign
tissue. Staining intensity was recorded as weak (+), moder-
ate (+ +) and strong (+ + +). The percentage of cells with
pRB nuclear or cytoplasmic staining was estimated as fol-
lows: loss in 95-100% (0), loss in 75-94% (1), loss in
50-74% (2) and loss in 0-49% (3).
Results
Patients and tumour stage andgrade
The age range of the 43 patients with prostate cancer was
55-88 (mean 72.8) years and of the ten with BPH was 61 to
80 (mean 71.9) years. The stages of the tumours were TIMO
(n = 1), T2MO (n = 6), T2M1 (n = 5), T3MO (n = 6), T3M1
(n = 12), T4MO (n = 5 and T4M1 (n = 8). The tumours were
graded as well (n = 5), moderately (n = 14) and poorly differ-
entiated (n = 24).
Loss ofheterozygosity in cancer tissue
Samples from 40 of 43 cancer patients were informative to
one or more DNA probes/PCR sequences (Table II). Overall
24 (60%) out of 40 tumours showed loss of heterozygosity at
one or more loci examined. Of these 24 patients, 4 (27%) out
of 15 informative cases showed loss with probe pl23ml.8, 11
(48%) out of 23 informative cases showed loss with probe
p68RS2.0 and 13 (54%) out of 24 informative cases showed
loss with PCR to RB1 intron 20 (Figure 1).
Twelve out of 24 cancers showing LOH exhibited a dele-
tion at the only intron at which the case was informative.
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Figure 1 Examples of loss of heterozygosity. a, LOH in a prostate cancer using probe pl23ml.8. b, LOH in cases of prostate
cancer using probe p68RS2.0. c, LOH in cases of prostate cancer by PCR of intron 20. d, LOH in patient E with BPH only and
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Seven cases showing LOH had losses at both of the two
informative introns for that patient. The remaining five
patients showed interstitial loss with preservation of part of
the gene. Loss of the 5' region with preservation ofthe 3' end
was shown by one tumour (number 10). Loss of the 3' region
with preservation of the 5' end was found in three tumours.
Loss of intron 17 with preservation of the flanking 5' and 3'
ends was seen in one case (number 39). Examination of gel
loading and comparison with the allele strength in infor-
mative cases gave no indication of any chromsomal duplica-
tions. One tumour (number 13) showed a rearrangement with
novel allele formation on PCR to intron 20 (Figure 2). This
PCR reaction was repeated with consistent results. All of the
tumour/blood DNA samples have been examined at 22
different chromosomal loci (unpublished data), mostly
VNTR polymorphisms. None of them, including tumour
number 13, showed any disparity between the allele size
displayed by tumour or blood DNA at these other loci,
indicating that there had been no error in sample labelling
during paired normal and tumour DNA extraction.
Prostate cancer is a diffusely infiltrating tumour, and the
densitometry readings were used to assess the degree of
background benign tissue contamination. Of those tumours
showing LOH, 15 had a 70% or greater reduction in the
signal strength of the deleted allele, six showed a 50-69%
reduction and three showed a 30-40% reduction in the
deleted allele. The last three cancers had a high precentage of
benign tissue contamination despite tumour microdissection.
Loss ofheterozygosity in BPH tissue
Of the nine informative benign (BPH) prostates, one showed
LOH to intron 1 (BamHI polymorphism) using probe
p123ml.8 and intron 17 (XbaI polymorphism) as revealed by
PCR (Figure Id). This tissue showed retention of the 3' locus
within intron 17 as revealed by probe p68RS2.0. Intron 17 is
large and the XbaI and VNTR polymorphism are 20kb
apart (Wiggs et al., 1988). Densitometry showed a greater
than 60% reduction in the size of the deleted allele from the
BPH tissue when compared with its counterpart derived from
blood.
Examination of the two loci showing loss in this patient
was repeated five times with consistent results. All of the
tissue resected from this 79-year-old patient (E) showed
benign hyperplasia with both epithelial and stromal elements.
There was no evidence ofmalignancy on histological examin-
ation, including the frozen section material used for DNA
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Figure 2 Demonstration of a novel allele in tumour DNA by
PCR of intron 20. N, normal DNA; T, tumour DNA; bp, base
pairs.
nodular prostate on rectal examination. A bone scan was
performed, which was normal, and the prostate-specific anti-
gen (PSA) was marginally elevated (20 ng l-1). The nodular-
ity of the prostate and the elevated PSA strongly suggest an
occult prostatic cancer. After reviewing the overall clinical
picture in this patient, further biopsy of the prostate gland
was not considered to be ethical, but he remains under
careful clinical follow-up.
Loss ofheterozygosity vs stage andgrade
RBl loss was similar between different stages and grades of
tumour. LOH within tumours confined to the prostate (TI
and T2) was 60% (6/10); loss within those with extracapsular
spread of tumour (T3 and T4) was also 60% (18/30). The MO
tumours showed LOH in 56% (9/16) cases; those with bone
metastases (MI) showed loss in 62% (15/24) cases. Well-
differentiated tumours showed loss in 80% (4/5) cases,
moderately differentiated tumours showed loss in 71% (10/
14) of cases and the poorly differentiated tumours showed
LOH in 48% (10/21) of cases. There was no correlation
between loss of RB1 and the grade or stage of tumour.
Immunohistochemistry
Of the nine tumour patients examined, four had shown a
deletion of RB1, four were informative without LOH and
one was non informative to all introns examined. Seven
showed complete loss of pRB and two showed marked
reduction of tumour nuclear staining (Table III). Seven of
the tumours also contained areas of BPH within the sections
examined, and a higher percentage and a greater intensity of
nuclear staining was seen in the BPH cells than in adjacent
tumour cell nuclei (Figure 3). All four cases with BPH alone
showed greater staining than the tumours. There was no
relationship between the proportion of nuclei showing loss of
pRB staining and the reduction of the allele signal (as
assessed by densitometry) in those showing LOH. This may
have been because the material used for immunohistochemis-
try was from different prostatic curettings to those used for
microdissection and DNA extraction.
Discussion
Loss of heterozygosity within the RBl gene was identified in
60% of prostate cancers, which is higher than has previously
been reported (Carter et al., 1990; Macoska et al., 1992;
Table II Immunohistochemistry resultsindicatingpercentageofcells
showing loss of pRB staining
Patient Tumour Tumour BPH BPH
no. nucleus cytoplasm nucleus cytoplasm Stroma
Tumours
8 1++ 3++ 3++ 1+ 0
9 0 3+++ 3++ 1+ oa
18 0 0 1++ 1+ 0
21 1 + + + 2+ NA NA
I + + +a
22 0 3+ + NA NA 0
31 0 3++ 2++ 1+ 0
33 0 0 1++ 0 0
35 0 0 1+++ ob 0
42 0 2+ 2+ + + 3+b 0
BPH
A NA NA 3+ ++ I+ + ++b 0
C NA NA 2+ + + 2+ oa
I NA NA 2+ + 2+ + +b 0
J NA NA 3+++ 1+ 0
aEndothelial, inflammatory and transitional epitheliunm cells with
strong nuclearpRB staining. bPunctate pRB stainingwithincytoplasm.
Percentageofcellsshowinglossofstaining: 0,95-100%; 1, 75-94%;2,
50-74%; 3, 0-49%. Intensity of staining: +, weak; + +, moderate;
+ + +, strong. NA, not applicable; BPH, benign prostatic hyper-
trophy.1256 S.M.A. PHILLIPS et al.
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Figure 3 Demonstration of NCL-RB immunohistochemistry,
showing an area of benign glands with retention of nuclear pRb
(top) and an area of prostate tumour that has lost nuclear pRb
expressions (bottom).
Sarkar et at. 1992; Brooks et at., 1993) and is similar to that
for retinoblastoma tumours (Zhu et at., 1992). Point muta-
tions, not usually identified by RFLP studies, have been
identified as the somatic mutation in retinoblastomas (Dunn
et at. 1988). In non-hereditary retinoblastoma, after ex-
cluding those with gross gene alterations by Southern blot-
ting, point mutations of RBI1 were found in all seven
tumours examined (Yandell et at., 1989).
Carter et at. (1990) reported losses of RBlI in 3 out of 13
prostate cancers when combining the results of the intragenic
probe p68RS2.0 and a more distant probe to 13q. Results
were not given independently for the intragenic and chromo-
somal arm probes. Brooks et at. (1993) showed 27% loss of
RBI in prostate cancer when examining RBI intron 20 alone.
Sarkar et al. (1992) looked for deletions within the DNA of
the RBl promoter region and within exon 21 mRNA. They
found an abnormal short-sized mRNA transcript of RB1
exon 21 extracted from a pure population of cells in tissue
culture (cell line DU 145), but not in their seven cancer cases.
No deletions within the promoter region were detected. The
techniques used, however, would not have detected deletions
lying outside the two loci studied or deletions of the whole of
the promoter or exon 21 loci. If the whole of these loci had
have been lost in the cases they studied, DNA or mRNA
from benign tissue contamination would have been amplified
to give a normal-sized band. Macoska et al. (1992) used only
a single chromosome 13q marker and accepted a high degree
of benign tissue contamination of tumour DNA. They found
no losses in 19 informative cases, possibly because of benign
DNA contamination and the fact that the probe used would
not detect the small intragenic deletions that we and other
workers have found within RB1.
The RBl gene consists of 27 exons spread over 200 kb of
genomic DNA (Hong et al., 1989), which poses problems for
the detection of small deletions. The cancer samples in this
study were informative at one or more loci studied in 93%
(40/43) -of cases. Combining the results of all four loci gave a
higher rate of allelic loss than the use of any single locus
alone. There were 12 cases in which the only informative
locus showed the allele loss. Small interstitial deletions of the
RB1 gene have been widely reported in a number of different
tumours, including bone and soft-tissue sarcomas (Wunder et
al., 1991), breast cancer (T'Ang et al., 1988) and bladder
cancer (Cairns et al., 1991).
In seven of the nine tumours immunohistochemistry show-
ed pRB loss in 95-99% of tumour nuclei. In the other two
cases loss was seen in 75-94% of tumour nuclei. The
presence of some pRB nuclear staining could be explained by
the presence of mutant pRB which may be functionally
inactive or by the retention a small clone of cells without
pRB loss. This may suggest that loss of RBI, though early, is
not the initiating event in carcinogenesis (Benedict et al.,
1990). Another possibility is that there is limited expression
of the retained RBI allele (possibly mutant), subject to
activity of controlling genes.
One patient with BPH showed loss of heterozygosity of
RB1, which may represent a premalignant field change occur-
ring within the gland. de Vere White et al. (1992) noted
abnormal RBI mRNA expression in 1 of 13 benign pros-
tates. Our case may be similar to this, though whether altera-
tion of RB1 is representative of a premalignant change or
has a role in prostatic adenoma or hyperplasia is unclear.
This study has shown that loss of RBl gene is a frequent
and possibly early event in prostatic tumorigenesis
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